Abstract:
The article examines the interrelationship between cardiovascular disease (CVD) and metabolic associated fatty liver disease (MAFLD), highlighting how MAFLD is an independent
cardiometabolic risk factor and emphasizing early detection and integrated management to reduce
cardiovascular risk. MAFLD prevalence is high globally and rising, especially among high-risk
groups; obesity, type 2 diabetes, dyslipidemia, and hypertension commonly cluster with MAFLD.
There is evidence linking MAFLD to subclinical and clinical CVD, with insulin resistance and
metabolic syndrome playing important roles; MAFLD may drive adverse myocardial remodeling and
diastolic dysfunction. Development of improved non-invasive biomarkers for inflammation and
fibrosis is a priority to better predict disease progression and guide treatment.
